Global liver cancer diagnostics market to grow nearly 2.1x from 2022 to 2032: Fact.MR study

The global liver cancer diagnostics market is expected to grow at a staggering CAGR of 8.2%, reaching USD 26 billion, after an assessment period ranging from 2022 to 2032. According to a recently published report on this industry by Fact .MR, a valuation of US$11.73 billion was projected in fiscal year 2022.

From 2017 to 2021, request for the diagnosis of liver cancer flourished at a growth rate of 7.8%, concluding at US$10.83 billion. The growing adoption of self-medication for the treatment of primary health conditions and the growing preference for dietary supplements in daily consumption are expected to boost the sales of over-the-counter vitamins and dietary supplements.

To stay “ahead” of your competition, request a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=73

Cancer cases have seen a substantial increase in the last decade, and this increase is also expected to continue in this decade. Liver cancer cases have seen a gradual increase as people’s lifestyles have changed drastically over the years. The prevalence of obesity due to unhealthy eating habits is one of the main factors responsible for the increase in liver cancers worldwide.

The increase in tobacco and alcohol consumption is also a major lifestyle change that has promoted the disease, in turn leading to increased demand for effective liver cancer diagnostics. Hepatocellular carcinoma (HCC) diagnosis and liver carcinoma diagnosis are two major diagnostic methods that are in demand and expected to be important in the decade.

Key insights from market research

  • Global Liver Cancer Diagnostics Market to Grow Nearly 2.1x Between 2022 and 2032
  • LFTs for liver cancer diagnostics are the most sought-after component, flourishing at a CAGR of 8.1%.
  • By end-user, the cancer research institutes segment is likely to register a CAGR of around 8%
  • The United States is going to become one of the most opportunistic markets, witnessing a significant growth rate throughout the forecast period 2022-2032

“Rising prevalence of cancer in major regions like North America and Europe and recent FDA approvals on new early detection tests for liver cancer are expected to accelerate the market growth.” comments a Fact analyst. Mr.

What makes the US liver cancer diagnostics market a hotspot?

Due to factors such as the presence of eminent vendors, increasing prevalence of related diseases, early acceptance of new methods, etc., the United States is a very attractive market for liver cancer diagnosis. As research in the country picks up pace, an increase in demand for liver cancer diagnostics from cancer research institutes is predicted.

Atezolizumab (Tecentriq) and bevacizumab (Avastin) received FDA approval in June 2020 as initial treatments for people with liver cancer that has spread or cannot be cured surgically. For people with the type of liver cancer known as hepatocellular carcinoma, this new drug appears to be superior to traditional (HCC) treatments.

For critical insights on this market, request methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=73

Competitive landscape

Prominent service providers are taking advantage of the rapid digitalization of the landscape to introduce new services equipped with cutting-edge innovative technology. Some notable developments are:

  • In August 2021, Illumina, Inc. announced the acquisition of GRAIL, a healthcare company focused on the early and life-saving detection of multiple cancers, but will own GRAIL as a separate company pending ongoing regulatory review of the European Commission.
  • In September 2021, the Indian company BDR Pharma announced the launch of the generic cancer drug called Cabozantinib. The drug is said to be useful in the treatment of hepatocellular carcinoma and other types of cancers.
  • In June 2022, Adaptimmune and Genetech announced a collaboration through which they would commercialize allogeneic T-cell therapies to treat various cancers. This collaboration could generate around US$3 billion for the companies involved.
  • In August 2021, 111, a digital health platform, entered into a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co. to develop a virtual platform for people with liver cancer. The platform would provide patients with access to online medical consultations and medications.

Profiled Key Companies

  • Illumina Inc.
  • Foundation Medicine Inc.
  • Danaher Company
  • Sysmex Company
  • Biocept inc.

What role does imaging play in the diagnosis of liver cancer?

Imaging is essential for diagnosing cancer because it allows doctors to look at the size and type of tumors. There are many different imaging technologies and procedures to choose from, and imaging for the diagnosis of liver cancer is also a very common diagnostic tool. Fact.MR’s most recent report says researchers are working on new imaging techniques that may be more effective at detecting small cancers.

For example, a TLC-supported team of researchers is working with peptides, which are tiny chemicals that latch onto liver cancer cells. These peptides are connected to dyes visible on a scanner or MRI. Several imaging methods and technologies include:

  • Endoscopy for the diagnosis of liver cancer
  • Computed tomography (CT) for the diagnosis of liver cancer
  • Magnetic resonance imaging (MRI) for the diagnosis of liver cancer
  • Ultrasound Imaging for the Diagnosis of Liver Cancer
  • MRI imaging tests for the diagnosis of liver cancer
  • Laparoscopic tests for the diagnosis of liver cancer

Get full access to this report through our PayPal payment option: https://www.factmr.com/checkout/73

Key Segments of the Liver Cancer Diagnostics Industry Research

  • By type of test:
    • AFP testing
    • LFT
    • Biopsy
    • Others
  • Per end user:
    • Hospital laboratories
    • Independent diagnostic laboratories
    • Cancer research institutes
    • Others
  • By region:
    • North America
    • Europe
    • Asia Pacific
    • The Middle East and Africa
    • Latin America

Check out Fact.MR’s healthcare coverage:

Cancer Profiling Market: The global cancer profiling market is expected to generate significant gains in 2021 as the preference for precision medicine and high-quality oncology care gains increasing traction. As the global cancer burden is set to proliferate, patients and physicians are striving to offer highly effective and sustainable cancer diagnostics, prompting the entry of many service providers.

Cancer RNA Expression Market: Cancer worldwide is one of the leading causes of death and an effective way to treat it still seems incomplete in most parts of the world. The factors that influence the success of cancer treatment are different depending on the stage of diagnosis, the availability of treatment and the availability of qualified health professionals associated with the high economic burden of the disease.

Cancer Genomic Testing Market: Cancer genomic testing is a new area of ​​genetics that is used to diagnose different types of cancer. Cancer genomic testing is completely different from genetic testing because during genomic testing, the entire gene of the patient is tested. Alteration or mutation of genes is the main factor causing cancer. During cancer genomic testing, the alteration or mutation of the gene is tested.

Cancer Therapeutics Market: The global cancer treatment market is estimated to be worth USD 12.1 billion in 2022 and is expected to exceed USD 28.3 billion by 2032, growing at a CAGR of 8.8% from 2022 to 2032. cancer treatments is likely to create an absolute dollar opportunity of USD 16.2 billion by the end of 2032. The global cancer treatments market holds approximately 12% of the global treatments market.

Cancer Immunotherapy Market: The cancer immunotherapy market was worth US$119.4 billion by 2021, according to Fact.MR, a market research and intelligence provider. The market is expected to surpass US$310 billion by registering a staggering CAGR of 10% by the end of the 2021-2031 valuation period.

About Us:
Market research and consulting agency that makes the difference! That’s why 80% of Fortune 1000 companies trust us to make their most critical decisions. Although our experienced consultants use the latest technology to extract hard-to-find information, we believe that our USP is the trust our clients place in our expertise. Covering a wide range – from automotive and Industry 4.0 to healthcare and retail, our coverage is extensive, but we ensure that even the most niche categories are analyzed. Our sales offices in the USA and Dublin, Ireland. Headquarters based in Dubai, United Arab Emirates. Contact us with your goals and we will be a competent research partner.

Contact:
Mahendra Singh
USA Sales Office:
11140 Rockville Pike
Office 400
Rockville, MD 20852
E-mail: [email protected]
Such : +1 (628) 251-158

Comments are closed.